Is positron emission tomography–computed tomography (PET‑CT) sufficient for routine surveillance of breast cancer in a woman with a breast implant after mastectomy or lumpectomy?

PET-CT is NOT adequate as routine surveillance for breast cancer in patients with breast implants

PET-CT should not be used for routine surveillance of breast cancer in women with breast implants after mastectomy or lumpectomy. Current guidelines do not support its use in this setting, and clinical examination remains the primary surveillance method for the postmastectomy breast 1.

Why PET-CT is Not Recommended for Routine Surveillance

Guideline Position

The ACR Appropriateness Criteria explicitly states there is no relevant literature to support the use of FDG-PET breast for screening in the postmastectomy setting 1. This applies regardless of whether reconstruction was performed with implants or autologous tissue. The guidelines emphasize that:

• Clinical evaluation remains the mainstay for postmastectomy surveillance
• Recurrence rates are approximately 1-2% annually after mastectomy with or without reconstruction
• Most recurrences occur in skin and subcutaneous tissues, followed by areas deep to the pectoralis muscle 1

When PET-CT IS Appropriate

The 2024 EANM-SNMMI joint guideline clarifies that PET-CT has a defined role only in specific clinical scenarios 2:

• Suspected recurrence: When there are clinical symptoms, palpable findings, or rising tumor markers (CA 15.3 or CEA)
• Equivocal conventional imaging: When mammography, ultrasound, MRI, CT, or bone scan show uncertain findings
• Known recurrence staging: To determine extent of metastatic disease

In these contexts, PET-CT demonstrates excellent performance with sensitivity of 90-96%, specificity of 81-91%, and changes management in 40-50% of patients 2, 3.

Specific Considerations with Breast Implants

Potential False Positives

A critical caveat: breast implants can cause false-positive PET findings due to inflammation around foreign materials 4, 5. One study documented FDG-avid lymph nodes from silicone-induced inflammation years after implantation, even without malignancy 5. This significantly reduces specificity in the implant population.

Surveillance Algorithm for Implant Patients

For asymptomatic patients:

• Clinical breast examination at regular intervals
• Mammography/DBT for the contralateral native breast annually 1
• No routine PET-CT

For symptomatic patients or clinical concern:

1. Start with targeted ultrasound or MRI of the area of concern
2. If findings remain equivocal after conventional imaging, then consider PET-CT 2
3. Be aware that FDG uptake may represent implant-related inflammation rather than recurrence 4, 5

Common Pitfalls to Avoid

• Do not order PET-CT for routine follow-up in asymptomatic patients—this leads to unnecessary radiation exposure, cost, and potential false positives from implant-related inflammation
• Do not skip conventional imaging and jump directly to PET-CT when symptoms arise—the implant presence makes interpretation more challenging
• Do not assume all FDG-avid findings represent recurrence in implant patients—silicone lymphadenitis can mimic malignancy 5

The evidence is clear and consistent: reserve PET-CT for problem-solving in symptomatic patients or when conventional imaging is inconclusive, not for routine surveillance 1, 2.